發送短信 : Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

 _    _     ______    _____    __   __   __   __  
| |  | ||  /_   _//  |__  //   \ \\/ //  \ \\/ // 
| |/\| ||   -| ||-     / //     \ ` //    \   //  
|  /\  ||   _| ||_    / //__     | ||     / . \\  
|_// \_||  /_____//  /_____||    |_||    /_//\_\\ 
`-`   `-`  `-----`   `-----`     `-`'    `-`  --`